Related Experiment Video
Updated: Jun 7, 2025
Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
Published on: August 25, 2023
Therapeutic targets for lung cancer: genome-wide Mendelian randomization and colocalization analyses
Yi Luan1,2, Desheng Xian3, Changwen Zhao3
1Laboratory Testing and Diagnosis Technology Department of Guangzhou National Laboratory, Clinical Laboratory of Sun Yat-sen Memorial Hospital, Guangzhou, Guangdong, China.
Background:
Lung cancer, categorized into non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), remains a significant global health challenge. The development of drug resistance and the heterogeneity of the disease necessitate the identification of novel therapeutic targets to improve patient outcomes.
Methods:
We conducted a genome-wide Mendelian randomization (MR) and colocalization analysis using a comprehensive dataset of 4,302 druggable genes and cis-expressed quantitative trait loci (cis-eQTLs) from 31,884 blood samples. The study integrated genomic analysis with eQTL data to identify key genes associated with lung cancer risk.
Results:
The analysis revealed five actionable therapeutic targets for NSCLC, including LTB4R, LTBP4, MPI, PSMA4, and TCN2. Notably, PSMA4 demonstrated a strong association with both NSCLC and SCLC risks, with odds ratios of 3.168 and 3.183, respectively. Colocalization analysis indicated a shared genetic etiology between these gene expressions and lung cancer risk.
Conclusion:
Our findings contribute to precision medicine by identifying druggable targets that may be exploited for subtype-specific lung cancer therapies.
Insights
This study identifies five new therapeutic targets for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). PSMA4 shows significant association with both lung cancer types, aiding precision medicine approaches.
Area of Science:
- Genomics
- Oncology
- Pharmacology
Background:
- Lung cancer, encompassing NSCLC and SCLC, presents a major global health burden.
- Drug resistance and disease heterogeneity underscore the need for novel therapeutic strategies.
- Identifying new drug targets is crucial for improving patient survival rates in lung cancer.
Purpose of the Study:
- To identify actionable, druggable genes associated with lung cancer risk.
- To explore potential therapeutic targets for both NSCLC and SCLC subtypes.
- To leverage genomic and eQTL data for precision medicine in lung cancer treatment.
Main Methods:
- Genome-wide Mendelian randomization (MR) analysis was performed.
- Colocalization analysis was conducted using cis-expressed quantitative trait loci (cis-eQTLs).
- Data from 4,302 druggable genes and 31,884 blood samples were analyzed.
Main Results:
- Five actionable therapeutic targets for NSCLC were identified: LTB4R, LTBP4, MPI, PSMA4, and TCN2.
- PSMA4 showed a strong association with both NSCLC (OR=3.168) and SCLC (OR=3.183) risks.
- Colocalization analysis confirmed a shared genetic basis between gene expression and lung cancer risk.
Conclusions:
- The study identified druggable targets for precision medicine in lung cancer.
- Findings support the development of subtype-specific therapies for NSCLC and SCLC.
- PSMA4 is highlighted as a potential therapeutic target for both major lung cancer types.
